CEO: Dr. Frank M. Torti M.B.A., M.D., MBA

IPO: 2019-06-21

Headquarters: US

Employees: 164

Homepage

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

Kamada Ltd

Madrigal Pharmaceuticals Inc

Amgen Inc

Enanta Pharmaceuticals Inc

United Therapeutics Corp